The object of the present invention is a new cryopolymerization process that provides crosslinked polymeric materials in the form of a macroporous gel (cryogel) capable of sequestering (neutralize) the anticoagulant heparin, its low molecular weight derivatives (LMWH and ULMWH) and heparinoids, from aqueous solutions, physiological solutions and biological fluids, such as whole blood, serum and plasma. A further object of the invention are also crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtained by the cryopolymerization process of the invention that, thanks to said specific process, result to be comprised of varying proportions of HEMA and HEMA-R monomers. The molar ratio between the components (HEMA/HEMA-R) may vary between 99.9% HEMA:0.1% HEMA-R and 0.1% HEMA:99.9% HEMA-R. Object of the invention is also the use of crosslinked polymeric materials in the form of a macroporous gel (cryogel) obtainable by the cryopolymerization process of the invention for the construction of filters, membranes or devices for the treatment of biological fluids. A further object of the invention are therefore filters, membranes, or devices for the treatment of biological fluids which comprise materials obtained by the cryopolymerization process of the invention.

Multicomponent copolymers including two or more types of repeat units is presented. In one example, the multicomponent copolymer includes at least one repeat unit AC having a structure (I), at least one repeat unit DC having a structure (II), and at least one repeat unit BC having a structure (III) or (V). The multicomponent copolymer may be cross-linked via a cross-linking agent. A polymer blend including the multicomponent copolymer or a cross-linked copolymer and a second polymer is also provided. The multicomponent copolymer may be a random or a block copolymer. The structural units of the multicomponent copolymers provide improved, tunable properties, such as improved biocompatibility and hydrophilicity, protein fouling, and mechanical properties, to the copolymers and/or the membranes fabricated from the copolymers.

A hydrogen peroxide production method, system, and apparatus is provided for producing large volumes of hydrogen peroxide having concentrations up to and excess of 80% in one continuous cycle. In one aspect, the hydrogen peroxide production system can include an aqueous solution comprised of an NQO1 enzyme, an NQO1 activated compound or molecule, and an NADH or NADPH cofactor for producing hydrogen peroxide, a production chamber having a semi-permeable membrane for receiving the aqueous solution. Here, the membrane can further include one or more molecular weight barriers configured to diffuse the produced hydrogen peroxide there through. The system can also include a collection chamber for receiving the produced hydrogen peroxide, and one or more pumps for circulating the aqueous solution having the hydrogen peroxide to the collection chamber and back to the production chamber.

The present invention concerns an electronic safety system for an RO device which is configured to be used with at least one dialysis device (e.g., a hemodialysis or a peritoneal dialysis device). The system comprises the RO device, which is configured for the production of ultrapure water and which includes a sensor unit for collecting sensor data and whereby the RO device comprises an electronic data interface in order to send the sensor data collected by the sensor unit; and it also comprises an analysis unit which is configured to analyze a water sample with regards to safety requirements and for example with regard to contamination and to generate result data whereby the analysis unit also includes an analysis interface in order to send the generated result data in electronic form; and a network for the data exchange between the medical entities, for example between the RO device and the analysis unit.

The present invention provides an organic bioelectronic HD device system for the effective removal of protein-bound substances, comprising PEDOT:PSS, a multiwall carbon nanotube, polyethylene oxide (PEO), and (3-glycidyloxypropyl)trimethoxysilane (GOPS). The composite nanofiber platform exhibited (i) long-term water-resistance; (ii) high adhesion strength on the PES membrane; (iii) enhanced electrical properties; and (iv) good anticoagulant ability and negligible hemolysis of red blood cells, suggesting great suitability for use in developing next-generation bioelectronic medicines for HD.

A multilayer nano-cell includes an innermost water phase core including biomolecules in an aqueous solution; a first layer, including an oil phase layer encapsulating the innermost water phase core, thereby forming a water-in-oil structure, the oil phase layer including caprylic/capric triglyceride and macrogol-35-glycerol-rizinoleat; a second layer, including a water phase layer encapsulating the first layer, the water phase layer including hyaluronic acid, Cu-GHK tripeptide, palmitoyl-KTTKS pentapeptide, and hexapeptide argireline; a third layer, including another oil phase layer encapsulating the second layer; a fourth layer, including another water phase layer encapsulating the third layer; a fifth layer, including another oil phase layer encapsulating the fourth layer; and a sixth layer, including an outmost cream layer encapsulating the fifth layer.

A substance separating device includes a reaction vessel provided with an interior that is partitioned into a first chamber and a second chamber by a dialysis membrane, a solution being stored in the reaction vessel. A specimen is stored in the first chamber, and dye-modified molecule that has a binding ability for specifically binding to a substance to be measured having a molecular weight greater than a molecular weight cut-off the dialysis membrane is stored in at least one of the first chamber and the second chamber. The dye-modified molecule has a molecular weight that is less than the molecular weight cut-off of the dialysis membrane.

The present disclosure relates to systems and methods for the separation of blood into blood products and, more particularly, to systems and methods that permit automated recovery of white blood cells after producing a leukocyte-reduced blood product.

The present disclosure relates to systems and methods for the separation of blood into blood products and, more particularly, to systems and methods that permit automated recovery of white blood cells after producing a leukocyte-reduced blood product.

The present invention relates to a method for measuring activity of HAO which comprises bringing HAO into contact with hydroxylamine in the presence of a tetrazolium salt. Further, the present invention also provides a method for culturing microorganisms which comprises culturing microorganisms in a storage container of a sample containing microorganisms installed separately in a liquid medium storage container, wherein the storage container of a sample containing microorganisms has pores.